S&P Futures
4,245.25 -41.25 (-0.96%) Dow Futures
33,716.00 -265.00 (-0.78%) Nasdaq Futures
13,378.50 -144.75 (-1.07%) Russell 2000 Futures
1,977.90 -23.80 (-1.19%) Crude Oil
88.70 -1.80 (-1.99%) Gold
1,764.80 -6.40 (-0.36%)
La Jolla Pharmaceutical Company (LJPC)
After hours:
Chart Events
Performance Outlook
| Previous Close | 6.17 |
| Open | 6.18 |
| Bid | 0.00 x 2200 |
| Ask | 0.00 x 1400 |
| Day's Range | 6.16 - 6.22 |
| 52 Week Range | 3.07 - 6.22 |
| Volume | |
| Avg. Volume | 284,632 |
| Market Cap | 155.108M |
| Beta (5Y Monthly) | 2.41 |
| PE Ratio (TTM) | 38.88 |
| EPS (TTM) | 0.16 |
| Earnings Date | Nov 02, 2022 - Nov 07, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.23 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for LJPC
Related Research
- La Jolla Pharmaceutical CompanyThe Argus High-Yield Model PortfolioValue stocks -- a market segment that includes high-yield stocks -- are outperforming growth stocks in 2022 for the first time since 2016. Indeed, for the past decade, the performance record has favored growth. In nine of the past 10 years, growth stocks have topped value stocks. But the tide may be turning. The rollout of COVID-19 vaccines has given a lift to some of the cyclical companies (energy companies and regional banks) that have lagged in recent quarters, and value stocks have kept up the pace with growth stocks in the past year. Now, the Federal Reserve lifting interest rates to fend off inflation, which will likely cap multiple expansion for growth companies. Regardless, the value sector is the place to achieve income. The current yield on the iShares Russell 1000 Value Index ETF is 2.1%, compared to the 0.8% current yield on the iShares Russell 1000 Growth Index ETF. For our High-Yield Theme Model Portfolio, we are seeking stocks with yields of at least 3.0%. This moves us deep into the value segment of the market.RatingFair ValueEconomic Moat15 hours agoArgus Research
- American City Business Journals
Biotech M&A returns as Vertex, Innoviva make buys
Come, thou long-expected M&A. On Monday, Vertex Pharmaceuticals Inc. and Innoviva Inc. both announced that they were making acquisitions. Vertex (Nasdaq: VRTX) is set to buy ViaCyte, a cell therapy startup specializing in diabetes, for $320 million cash, while Innoviva will pay about $149 million for infectious diseases firm La Jolla Pharmaceutical Company (Nasdaq: LJPC).
- American City Business Journals
How this Peninsula company is turning lung drug royalties into acquisitions
With the help of nearly $400 million in royalties from a well-known drug targeting asthma and COPD, the company wrapped up one acquisition and launched another.
- Benzinga
Innoviva Bolsters Its Infectious Disease, Hospital Portfolio With La Jolla Deal
Innoviva Inc (NASDAQ: INVA) has agreed to acquire La Jolla Pharmaceutical Company (NASDAQ: LJPC) for $5.95 per share, representing a premium of approximately 70% to the 30-day volume-weighted average price. Innoviva will also pay an incremental $0.28 per share for additional cash proceeds received in connection with the divestiture of a non-core asset. The deal consideration of $6.23 per share in cash has an implied enterprise value of approximately $149 million. The FDA approved La Jolla's lead
